Jeff E. Knight - 22 Mar 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
22 Mar 2024
Net transactions value
-$714,275
Form type
4
Filing time
26 Mar 2024, 16:30:42 UTC
Previous filing
20 Mar 2024
Next filing
28 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $719,400 +30,000 +55% $23.98 84,939 22 Mar 2024 Direct
transaction CRNX Common Stock Sale $1,326,600 -30,000 -35% $44.22 54,939 22 Mar 2024 Direct F1
transaction CRNX Common Stock Sale $107,075 -2,359 -4.3% $45.39 52,580 22 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 -30,000 -19% $0.000000 130,000 22 Mar 2024 Common Stock 30,000 $23.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.22 per share. The range of sales prices on the transaction date was $44.00 to $44.52 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.